Estrella Immunopharma Inc

ESLA13 Dec 2024
Healthcare
$1.11
-0.06 (-6.07%)
Lowest Today
$1.11
Highest Today
$1.11
Today’s Open
$1.11
Prev. Close
$1.23
52 Week High
$3.23
52 Week Low
$0.63
To Invest in Estrella Immunopharma Inc

Estrella Immunopharma Inc

Healthcare
ESLA13 Dec 2024
-0.06 (-6.07%)
1M
3M
6M
1Y
5Y
Low
$1.11
Day’s Range
High
$1.11
1.11
52 Week Low
$0.63
52-Week Range
52 Week High
$3.23
0.63
1 Day
-
1 Week
-11.02%
1 month return
+36.29%
3 month return
+28.61%
6 month return
+23.46%
1 Year return
-16.55%
3 Years return
-87.77%
5 Years return
-
10 Years return
-
Fundamentals
Market Cap
49.93 mln
PB Ratio
66.9
PE Ratio
0
Enterprise Value
28.09 mln
Total Assets
4.45 mln
Volume

Fund house & investment objective

Company Information
Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103, which is in clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It has a collaborative agreement with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California.
Organisation
Estrella Immunopharma Inc
Employees
0
Industry
Biotechnology
CEO
Dr. Cheng  Liu Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities